Search

Displaying results 7531 - 7540 of 10000 in total
  1. Drug

    Picafibrate

    go.drugbank.com/drugs/DB19574
    Experimental

    Picafibrate has a monoisotopic molecular weight of 362.1 Da. … The usage of the INN stem '-fibrate' in the name indicates that Picafibrate is a clofibrate derivative, peroxisome proliferator activated receptor-a (PPAR-a) agonist.

  2. Drug

    Tiafibrate

    go.drugbank.com/drugs/DB19874
    Experimental

    Tiafibrate has a monoisotopic molecular weight of 686.23 Da. … The usage of the INN stem '-fibrate' in the name indicates that Tiafibrate is a clofibrate derivative, peroxisome proliferator activated receptor-a (PPAR-a) agonist.

  3. Drug

    Urefibrate

    go.drugbank.com/drugs/DB20849
    Experimental

    Urefibrate has a monoisotopic molecular weight of 354.02 Da. … The usage of the INN stem '-fibrate' in the name indicates that Urefibrate is a clofibrate derivative, peroxisome proliferator activated receptor-a (PPAR-a) agonist.

  4. Drug

    Sitofibrate

    go.drugbank.com/drugs/DB21192
    Experimental

    Sitofibrate has a monoisotopic molecular weight of 610.42 Da. … The usage of the INN stem '-fibrate' in the name indicates that Sitofibrate is a clofibrate derivative, peroxisome proliferator activated receptor-a (PPAR-a) agonist.

  5. Drug

    Zatonacaftor

    go.drugbank.com/drugs/DB21625
    Experimental

    Zatonacaftor has a monoisotopic molecular weight of 453.17 Da. … The usage of the INN stem '-caftor' in the name indicates that Zatonacaftor is a Cystic fibrosis transmembrane regulator (CFTR) protein modulator, corrector, and amplifier.

  6. Drug

    DDP-200

    go.drugbank.com/drugs/DB05919
    Experimental

    DDP200 is developed by Dynogen for the treatment of non-incontinent form of overactive bladder (OAB) with particular focus on both male and female patients with urinary frequency, urinary urgency and nocturia

  7. Drug

    ICA-105665

    go.drugbank.com/drugs/DB06089
    Investigational

    It is a novel opener of the KCNQ ion channel which in preclinical studies has demonstrated a broad spectrum of activity in models of epilepsy. … In addition, ICA-105665 has also demonstrated activity in certain models of neuropathic pain.

  8. Drug

    Aleglitazar

    go.drugbank.com/drugs/DB08915
    Investigational

    It is being investigated for use in patients with type II diabetes to reduce their risks of cardiovascular mortality and morbidity. … Aleglitazar is an investigational drug from the company Hoffmann–La Roche and is currently in a phase III clinical trial called ALECARDIO.

  9. Drug

    R411

    go.drugbank.com/drugs/DB05468
    Experimental

    It is a dual-acting competitive integrin antagonist (as compared to previously developed single integrin antagonists or SIAs) that prevents binding of V-CAM1 to either a4b1 or a4b7. … R411 is a non-steroid oral medicine for the treatment of asthma. It is not immunosuppressive, but blocks the activation and recruitment of cells involved in respiratory inflammation.

  10. Drug

    Vabametkib

    go.drugbank.com/drugs/DB21629
    Investigational

    Vabametkib has a monoisotopic molecular weight of 566.3 Da. … Vabametkib is under investigation in clinical trial NCT05541822 (To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET